The short version of peptide purity fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-15 and is reviewed periodically as new material appears.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
| Property | Value | Notes |
|---|---|---|
| Dry powder storage | -20 °C or below | Desiccated and protected from light |
| Solution storage | 2-8 °C, short term | Aliquot to avoid freeze-thaw cycling |
| Reconstitution solvent | Water or buffered saline | Near-neutral pH is generally preferred |
| Identity confirmation | Mass spectrometry | Matches expected monoisotopic mass |
| Purity assessment | Reverse-phase HPLC | Reported as main-peak area percentage |
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
=== Pregnancy === When given in the second or third trimesters of pregnancy, no artesunate-related adverse pregnancy outcomes have been reported. However, there is insufficient evidence regarding the safety of artesunate use in the first trimester of pregnancy. The WHO recommends that artesunate use for severe malaria in the first trimester should be based on the individual risks versus benefits. In absence of other viable treatment options, artesunate may be used.
Platinum-based antineoplastic drugs (informally called platins) are chemotherapeutic agents used to treat cancer. Their active moieties are coordination complexes of platinum. These drugs are used to treat almost half of people receiving chemotherapy for cancer. In this form of chemotherapy, commonly used drugs include cisplatin, oxaliplatin, and carboplatin, but several have been proposed or are under development. Addition of platinum-based chemotherapy drugs to chemoradiation in women with early cervical cancer seems to improve survival and reduce risk of recurrence. In total, these drugs can cause a combination of more than 40 specific side effects which include neurotoxicity, which is manifested by peripheral neuropathies including polyneuropathy.
== External links == 1965 Audio Interview with Alfred Nier by Stephane Groueff Voices of the Manhattan Project Annotated Bibliography for Alfred O.C. Nier from the Alsos Digital Library for Nuclear Issues "Nier Mass Spectrograph". National Museum of American History: Kenneth E. Behring Center. Smithsonian Institution. Archived from the original on 8 August 2007. Retrieved 2007-08-16. "Alfred Nier (in 1964) at his mass spectrograph which he used to separate a sample of U-235". University of Minnesota. Archived from the original on 2011-07-16. Retrieved 2010-09-05. "Alfred and Ardis Nier at Nier's retirement party". Emilio Segrè Visual Archives. American Institute of Physics. Archived from the original on 2007-07-14. Retrieved 2007-08-16. "Nier, Verbrugge and Newbury". Emilio Segrè Visual Archives. American Institute of Physics. Archived from the original on 2007-07-14. Retrieved 2007-08-16.
Sources: en.wikipedia.org
"Tetrachlorodecaoxide" (TCDO) is a chlorite-containing substance with claimed immunomodulatory, macrophage-activating properties. WF10 (Macrokine, Immunokine, Oxoferin) is an aqueous solution of tetrachlorodecaoxide designed for intravenous injection. Tetrachlorodecaoxide/WF10 were originally developed by Oxo Chemie. The chemical formula is given as Cl4H2O114-. This incomplete formula shows a mixture of chlorite ion, water, and molecular oxygen: "Cl4H2O114-" = 4ClO2− + H2O + O2. Oxoferin was found to be equivalent with aqueous sodium chlorite. Tetrachlorodecaoxide / WF10 is used in the management of radiation cystitis, is effective in the treatment of diabetic foot ulcers, and is used in wound healing, where the mechanism of action is activation of the macrophage system, and increasing the partial pressure of oxygen in the wound.
=== Controversy and plasticity === In spite of a burgeoning literature supporting TPCs as the NAADP-regulated channel, this was challenged in 2012/13 by reports that TPCs are, instead, Na+ channels regulated by the endo-lysosomal lipid, Phosphatidylinositol 3,5-bisphosphate, PI(3,5)P2 and also by metabolic state (via ATP and mTOR). This controversy ultimately evolved into a new model of how TPCs work. The challenge raised two different, but interrelated issues: (a) TPCs are insensitive to NAADP; (b) TPCs are Na+- (and not Ca2+-) permeable.
Many of the opposition groups subsequently began competing for influence in the power vacuum that followed the ouster of Barre's regime. In the south, armed factions led by USC commanders General Mohamed Farah Aidid and Ali Mahdi Mohamed, in particular, clashed as each sought to exert authority over the capital. In 1991, a multi-phased international conference on Somalia was held in neighbouring Djibouti. Owing to the legitimacy bestowed on Muhammad by the Djibouti conference, he was subsequently recognised by the international community as the new President of Somalia. He was not able to exert his authority beyond parts of the capital. Power was instead vied with other faction leaders in the southern half of Somalia and with autonomous sub-national entities in the north. The Djibouti conference was followed by two abortive agreements for national reconciliation and disarmament, which were signed by 15 political stakeholders: an agreement to hold an Informal Preparatory Meeting on National Reconciliation, and the 1993 Addis Ababa Agreement made at the Conference on National Reconciliation. In 1998, the state of Puntland was established under the leadership of Abdullahi Yusuf, head of the Somali Salvation Democratic Front. In the early 1990s, due to the protracted lack of a permanent central authority, Somalia began to be characterised as a "failed state". Following the collapse of the Somali Democratic Republic in early 1991, a new phenomenon emerged – the establishment of Sharia courts to impose law and order on the volatile neighborhoods of Mogadishu.
Sources: en.wikipedia.org
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.
It normally reports the share of the chromatographic signal that belongs to the main peak, not a measure of activity. A high figure means few related substances were detected under the stated method and wavelength. Different laboratories and methods can return different values for the same material.
Retention time alone is weak evidence, because unrelated peptides can elute at similar positions. Amino acid analysis or peptide mapping gives stronger sequence information when a mass spectrometer is unavailable. Most laboratories still treat mass confirmation as the standard step for verifying the correct compound.
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.